Mark Cancilla

Title: Mark Cancilla: Innovator in Chemotype Evolution

Introduction

Mark Cancilla is a notable inventor based in San Mateo, CA. He has made significant contributions to the field of chemistry, particularly in the area of drug discovery and development. His innovative approach has led to advancements that can potentially streamline the process of identifying compounds that bind to target proteins.

Latest Patents

Mark Cancilla holds a patent for "Methods of Chemotype Evolution." This patent describes a method to rapidly screen a large chemical space for a compound that binds to a target protein through an iterative fragment assembly approach. This method can be performed at low reagent cost and does not require purification of the assembled product. The technique employs a library of test ligands, each comprising a 'bait' molecule known to have some intrinsic affinity for the target protein, along with a test moiety.

Career Highlights

Mark Cancilla is currently associated with Sunesis Pharmaceuticals, Inc., where he applies his expertise in chemistry to advance pharmaceutical research. His work has been instrumental in developing innovative methods that enhance the efficiency of drug discovery.

Collaborations

Throughout his career, Mark has collaborated with notable colleagues, including Stig Hansen and Daniel A Erlanson. These collaborations have fostered a productive environment for innovation and research in the pharmaceutical industry.

Conclusion

Mark Cancilla's contributions to chemotype evolution exemplify the impact of innovative thinking in the field of drug discovery. His work continues to influence the development of new therapeutic compounds, showcasing the importance of creativity and collaboration in scientific research.